曲拉西利预防化疗相关骨髓抑制的药物经济学探讨  

Pharmacoeconomics of trilaciclib in the prevention of chemotherapy⁃induced myelosuppression

作　　者：雷玮成 郭晨晨 杜宝萍 刘韬[1] 梁蔚婷[1] LEI Wei-cheng;GUO Chen-chen;DU Bao-ping;LIU Tao;LIANG Wei-ting(State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China)

机构地区：[1]中山大学肿瘤防治中心,广东省恶性肿瘤临床医学研究中心,华南恶性肿瘤防治全国重点实验室,广州510060 [2]中山大学药学院,广州510006

出　　处：《中国新药杂志》2023年第23期2354-2359,共6页Chinese Journal of New Drugs

摘　　要：目前,化疗仍然在肿瘤综合治疗中占据着举足轻重的地位。化疗导致的骨髓抑制(chemotherapy-induced myelosuppression, CIM)是化疗最常见的不良反应,严重影响化疗质量及患者的生活质量,严重增加患者的治疗负担,同时消耗更多的医疗资源。曲拉西利是一种高效、选择性、可逆的细胞周期蛋白依赖性激酶4/6(cyclin-dependent kinase 4/6,CDK4/6)抑制剂。临床数据显示,曲拉西利可将骨髓细胞暂时停滞在G1期降低CIM发生率,减少化疗剂量调整和延迟的比例,增加化疗的耐受性以及减轻患者经济负担。本文就目前CIM带来的危害、CIM的临床预防、CIM治疗现状以及曲拉西利预防CIM及其药物经济价值进行系统阐述及探讨,为患者选择合理的CIM预防以及治疗方案提供科学参考。Chemotherapy still plays pivotal roles in the comprehensive treatment of tumors.Chemotherapy⁃induced myelosuppression(CIM)is the most common adverse event of chemotherapy,which has posed serious impacts on the anti⁃tumor efficacy of chemotherapy and the quality of patients'lives,and also resulted in increased treatment burden of patients and more medical resources at the same time.Trilaciclib is a highly potent,selective,reversible cyclin⁃dependent kinase 4/6(CDK4/6)inhibitor.Clinical data showed that trilaciclib could temporarily arrest bone marrow cells in G1 phase to reduce the incidences of CIM and the proportion of chemotherapy dose adjustment and delay,increasing the tolerance of chemotherapy and reducing the economic burden.This article systematically elaborates on the CIM⁃caused hazards,clinical prevention,and current status of treatment of CIM,as well as the roles of trilaciclib in the prevention of CIM and its economic value,aiming to provide scientific reference for patients to select reasonable prevention and therapeutic treatment regimens of CIM.

关 键 词：化疗 骨髓抑制 曲拉西利 药物经济学 

分 类 号：R979.1[医药卫生—药品]